Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

Cancer Immunology, Immunotherapy

Volumn 64, Issue 6, 2015, Pages 765-767

  Martin Liberal, Juan ^a   Furness, Andrew JS ^a,b   Joshi, Kroopa ^a,b   Peggs, Karl S ^b   Quezada, Sergio A ^b   Larkin, James ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetes; Melanoma; MK 3475; Nivolumab; PD 1; Pembrolizumab

Indexed keywords

GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA ANTIGEN; INFUSION FLUID; INSULIN; IPILIMUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DIABETES; AUTOIMMUNE DISEASE; CASE REPORT; COMPASSIONATE USE; CUTANEOUS MELANOMA; DIABETIC KETOACIDOSIS; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LETHARGY; MIDDLE AGED; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; IMMUNOLOGY; MELANOMA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84930413267     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1689-1     Document Type: Article

References (5)

1. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H et al (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198(1):63–69
2. Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ et al (2007) Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 125(1):16–25
3. Kochupurakkal NM, Kruger AJ, Tripathi S, Zhu B, Adams LT, Rainbow DB et al (2014) Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One 9(2):e89561
4. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465
5. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM et al (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89(8):3896–3902